Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Second Primary Malignancies in Patients with MM
Biol Blood Marrow Transplant; ePub 2018 Jan 12; Sahebi, et al
Second primary malignancy (SPM) incidence in patients with multiple myeloma (MM) was similar to historical estimates, according to a study involving >3,200 individuals. Participants had MM and underwent a first autologous hematopoietic stem cell transplant between 2008 and 2012. Those with poor or potentially poor stem cell mobilization received plerixafor to stimulate mobilization. Among the results:
- 135 patients developed SPM.
- Cumulative incidence was 5.3% at 72 months.
- 94 patients developed solid tumors, 30 hematologic malignancies, and 11 unknown types of SPMs.
- Cumulative incidence of known hematologic malignancies was 1.4%; solid malignancy incidence was 3.6%.
- Those aged >65 years had an increased risk of SPM.
- Radiotherapy use, type of induction regimen, hematopoietic stem cell dose, poor mobilizer status, plerixafor use, and gender had no impact on of SPM incidence.
Sahebi F, Iacobelli S, Sbianchi G, et al. Incidence of second primary malignancies after autologous transplantation for multiple myeloma in the era of novel agents. [Published online ahead of print January 12, 2018]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2018.01.006.